Back to top
more

Allena Pharmaceuticals, Inc. (ALNA)

(Delayed Data from NSDQ)

$6.30 USD

6.30
60,678

+0.20 (3.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Allena Pharmaceuticals, Inc. [ALNA]

Reports for Purchase

Showing records 81 - 100 ( 170 total )

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

11/14/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

11/11/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

11/11/2019

Company Report

Pages: 10

Positive Topline Phase 3 URIROX-1 and Study 206 Data.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

11/08/2019

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

11/07/2019

Company Report

Pages: 9

It Is a Buy, Not Sell - Read Our Report to Figure Why

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

11/07/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

10/18/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

10/17/2019

Company Report

Pages: 10

Learning From History Lessons to Predict URIROX-1 Data - Must Read

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

10/17/2019

Company Report

Pages: 10

Presentations on Reloxaliase and ALLN-346 at ASN Kidney Week and ACR/ARP

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

10/08/2019

Company Report

Pages: 12

Proprietary Survey of 42 Docs Reveals Bullish View of Reloxaliase for EH

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

10/08/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

10/04/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

10/04/2019

Company Report

Pages: 8

Join Our Call Oct. 16 at 12PM ET to Decode Ph3 URIROX-1 Readout Scenarios

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

10/01/2019

Industry Report

Pages: 16

Biotechnology - Monthly Check-Up: October 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

09/19/2019

Daily Note

Pages: 10

KOL Enthusiastic About Reloxaliase; Next Phase 3 URIROX-1 Data in Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

09/19/2019

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 97

09/19/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 98

09/19/2019

Company Report

Pages: 13

Lots of Nuances Learned at Yesterday''s Analyst Day

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 50.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 99

09/17/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Allena Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 100

09/17/2019

Company Report

Pages: 8

Reloxaliase Ph3 URIROX-1: Fully Enrolled; On-Track to Report Data in Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party
// eof